This technology proposes the protein Mena as a therapeutic target for Alzheimer’s disease. These inventors discovered a novel Mena-RNP complex that regulates protein translation in neurons. Two of the proteins this Mena-RNP complex regulates are Dyrk1a and amyloid precursor protein (APP), which both have known roles in AD progression. Many of the AD clinical trials currently underway target aberrant aggregation of either APP or Tau protein. Targeting the Mena-RNP complex has the potential to modulate both of these proteins by directly reducing APP protein expression and indirectly reducing Tau aggregation by decreasing phosphorylation by Dyrk1a. In conclusion, this technology is an exciting new molecular target for AD that has the potential to inhibit both Tau and Amyloid aggregation.